<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00651911</url>
  </required_header>
  <id_info>
    <org_study_id>L_8637</org_study_id>
    <nct_id>NCT00651911</nct_id>
  </id_info>
  <brief_title>Fasturtec TLS Treatment / Prophylysis</brief_title>
  <official_title>A Multicenter Open Label Study of the Efficacy and Safety of Rasburicase in the Treatment of Prophylysis for Tumor Lysis Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      An open-label study to determine the efficacy and safety of Rasburicase used for the
      prevention and treatment of tumor lysis syndrome
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">July 2004</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the uricolytic response to rasburicase treatment</measure>
    <time_frame>5 weeks (3 to 7 days of treatment, with follow-up of 4 weeks after the last study drug injection)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate tumor lysis risk factors, treatments for tumor lysis syndrome and complications of treatment in patients treated prophylactically or therapeutically for tumor lysis syndrome</measure>
    <time_frame>5 weeks (3 to 7 days of treatment, with follow-up of 4 weeks after the last study drug injection)</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">45</enrollment>
  <condition>Tumor Lysis Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>urate oxidase</intervention_name>
    <description>First injection of Rasburicase will be done the day of initiation of chemotherapy, or the day before, according to hyperuricemia. Additional doses are permitted q12h during the first 72 hours of chemotherapy if hyperuricemia persists or subject is considered to be at significant risk of tumor lysis complications.</description>
    <other_name>rasburicase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chemotherapy planned for at least 3 cycles

          -  Undergoing cytoreductive chemotherapy for ALL, multiple myeloma or Burkitt's lymphoma
             stage III or IV

          -  With a minimum life expectancy of 3 months

          -  Uric acid &gt; 8 mg%

          -  Negative pregnancy test &lt; or =to 2 weeks and efficient contraceptive method.

          -  Negative HIV serology &lt; or =to 4 weeks

          -  Patient or legal guardian has signed a written informed consent

        Exclusion Criteria:

          -  Hypersensitivity to uricases or any of the excipients

          -  Known history of G6PD deficiency.

          -  Previous treatment with Rasburicase or UricozymeÂ®

          -  Pregnancy or lactation

          -  Treatment with any investigational drug within 30 days before planned first
             Rasburicase administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon Chang</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2008</study_first_submitted>
  <study_first_submitted_qc>March 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2008</study_first_posted>
  <last_update_submitted>March 31, 2008</last_update_submitted>
  <last_update_submitted_qc>March 31, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2008</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Tumor Lysis Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rasburicase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

